Background: Polycystic ovary syndrome (PCOS), the most prevalent hormonal disorder in females, is characterized by low levels of progesterone, which causes increased estrogen levels leading to production of various anti and auto-antibodies. This study aimed to estimate and compare levels of anti-nuclear antibodies (ANA), anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-TG), and anti-islet cell antibodies (anti-ICAb) in patients with PCOS and healthy controls.
Methods: The present comparative study included 82 subjects divided into two groups with 41 individuals in each group. Group I included healthy subjects, while Group II included patients diagnosed with PCOS. Blood samples were collected to determine serum levels of ANA, anti-TPO, anti-TG, and anti-ICAb using commercially available ELISA kits. Data were analyzed by using SPSS 20.0.
Results: Two (4.8%) subjects in Group II had ANA, but none of the other healthy individuals had these auto-antibodies. Levels of anti-TPO were higher in Group II (6.01 IU/ml) than in Group I (5.98 IU/ml). Levels of anti-TG and anti-ICAb were higher in Group I (19.86 and 32.49 IU/ml, respectively) than in Group II (19.78 and 26.07 IU/ml, respectively).
Conclusion: Levels of ANA and anti-TPO were higher in patients with PCOS than in controls. By contrast, levels of anti-TG and anti-ICAb were higher in controls than in patients with PCOS.
1. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: A major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol. 2009;2:232–9.
2. Lee H, Sung Y. Epidemiology and diagnostic criteria of polycystic ovary syndrome. J Korean Diabetes. 2015;16:189–93.
3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The androgen excess and pcos society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456–88.
4. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–36.
5. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685–97.
6. Balen AH, Laven JSE, Tan S, Dewailly D. Ultrasound assessment of the polycystic ovary syndrome: International consensus definitions. Eur Soc Hum Reprod Embroyol. 2003;9:505–14.
7. Sharquie KE, Al-Bayatti AA, Ajeel AI, Al-Bahar AJ, Al-Nuaimy AA. Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestation in patients with polycystic ovary syndrome. Saudi Med J. 2007;28:1039–43.
8. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91:4237–45.
9. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr Rev. 2012;33:981-1030.
10. Eshre TR, ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility Sterility. 2004;81:19–25.
11. Raja A, Hashmi SN, Sultana N, Rashid H. Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. J Ayub Med Coll Abbottabad. 2005;17:50–3.
12. Johansson J, Stener-Victorin E. Polycystic ovary syndrome: Effect and mechanisms of acupuncture for ovulation induction. Evid Based Complement Alternat Med. 2013;2013:762615.
13. Burt Solorzano CM, Beller JP, Abshire MY, Collins JS, McCartney CR, Marshall JC. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids. 2012;77:332–7.
14. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004;25:235–75.
15. Charlton H. Hypothalamic control of anterior pituitary function: a history. J Neuroendocrinol. 2008;20:641–6.
16. Meethal SV, Liu T, Chan HW, Ginsburg E, Wilson AC, Gray DN, et al. Identification of a regulatory loop for the synthesis of neurosteroids: a steroidogenic acute regulatory protein dependent mechanism involving hypothalamic pituitary gonadal axis receptors. J Neurochem. 2009;110:1014–27.
17. Veldhuis JD, Keenan DM, Liu PY, Iranmanesh A, Takahashi PY, Nehra AX. The aging male hypothalamic–pituitary–gonadal axis: Pulsatility and feedback. Mol Cell Endocrinol. 2009;299:14–22.
18. Roland AV, Moenter SM. Reproductive neuroendocrine dysfunction in polycystic ovary syndrome: Insight from animal models. Front Neuroendocrinol. 2014;35:494-511.
19. Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol. 2000;32:181–97.
20. Janssen OE, Mehlmauer N, Hahn S, Offner AH, Gartner R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol. 2004;150:363–9.
21. Saravanan P, Dayan CM. Thyroid autoantibodies. Endocrinol Metab Clin North Am. 2001;30:315–37.
22. Orgiazzi J. Anti–TSH receptor antibodies in clinical practice. Endocrinol Metab Clin North Am. 2000;29:339–55.
23. Fröhlich E, Wahl R. Thyroid autoimmunity: Role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases. Front Immunol. 2017;8:521.
24. Glinoer D, Braverman LE, Utiger LD. Werner and ingbar's the thyid: A fundamental and clinical text. Philadelphia: Williams and Wilkins. 2005:1086–108.
25. Dehaghani AS, Karimaghaei N, Parsanezhad ME, Malekzadeh M, Mehrazmay M, Erfani N. Anti-nuclear antibodies in patients with polycystic ovary syndrome before and after laparoscopic electrocauterization. Iran J Med Sci. 2013;38:187.
26. Makled AK, Fathi HM, Gomaa MF, Bakr RM. Serologic markers of autoimmunity in women with polycystic ovary syndrome. Middle East Fertil Soc J. 2015;20:86–90.
27. Aboud RS, Salloom DF, Abbas AH. Detection of type 2 diabetes mellitus in serum from women with polycystic ovarian syndrome. Baghdad Sci J. 2013;10:324–30.
28. Sinha U, Sinharay K, Saha S, Longkumer TA, Baul SN, Pal SK. Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern India. Indian J Endocrinol Metab. 2013;17:304.
29. Ganie MA, Kalra S. Polycystic ovary syndrome-A metabolic melady, the mother of lifestyle disorders in women- can Indian health budget tackle it in the future? Indian J Endocrinol Metab. 2011;15:239–41.
30. Mohammed S, Awooda HA, Rayis DA, Hamdan HZ, Adam I, Lutfi MF. Thyroid function/antibodies in sudanese women with polycystic ovarian disease. Obstet Gynecol Sci. 2017;60:187–92.
31. Oun AR, Rashed RM, Almraghy Y, ElBasuone WM, Midan MF. Autoimmune markers and Polycystic Ovary Syndrome. Nat Sci. 2014;12.
32. Escobar-Morreale HF, Roldán B, Barrio R, Alonso M, Sancho J, de la Calle H, et al. High prevalence of the polycystic ovarian syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2000;85:4182–7.
33. Hassan M, Hussein M, El-Wakil W. Serological autoimmune markers in women with polycystic ovary syndrome. Life Sci J. 2014;11:318–22.
34. Peppard HR, Marfori J, Iuorno MJ, Nestler JE. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care. 2001;24:1050–2.
35. Begum S, Hossain MZ, Rahman MF, Banu LA. Polycystic ovarian syndrome in women with acne. J Pak Assoc Dermatol. 2017;22:24–9.
Mobeen H, Kashif M, Nadeem A, Shahzad F, Tahir R, Abbas A, et al. Serum immune profiling of patients with polycystic ovary syndrome. Makara J Health Res. 2020;24.